KOREA WHO
-
-
CEO of AprilBio
Cha Sang-hun
Professor-Turned-CEO Leads AprilBio’s Billion-Dollar Global Push
-
Last Updated on Nov 14, 2025
-
CEO of AprilBio
Copy Url : https://www.koreawho.com/profile/ChaSanghun- Life Summary
Cha Sang-hun is the CEO of AprilBio.
He aims to build a global biotech company centered on platform technology.
He was born in January 1963.
After majoring in environmental science at Kangwon National University, he earned his master’s and doctoral degrees in microbiology and immunology in the United States.
While serving as a professor at the College of Biomedical Science at Kangwon National University, he founded AprilBio in 2013 with his students as a university-based startup.
He holds SAFA, a platform technology that extends the half-life of therapeutic proteins.
He is recognized as a strategy-oriented leader focused on technology.
He is concentrating on advancing platform technology, expanding indications, and strengthening the global network.
#AprilBio #ChaSanghun #biotech #platformtechnology #SAFA #immunology #KangwonNationalUniversity #biopharma #innovation #globalexpansion
He aims to build a global biotech company centered on platform technology.
He was born in January 1963.
After majoring in environmental science at Kangwon National University, he earned his master’s and doctoral degrees in microbiology and immunology in the United States.
While serving as a professor at the College of Biomedical Science at Kangwon National University, he founded AprilBio in 2013 with his students as a university-based startup.
He holds SAFA, a platform technology that extends the half-life of therapeutic proteins.
He is recognized as a strategy-oriented leader focused on technology.
He is concentrating on advancing platform technology, expanding indications, and strengthening the global network.
#AprilBio #ChaSanghun #biotech #platformtechnology #SAFA #immunology #KangwonNationalUniversity #biopharma #innovation #globalexpansion
- Life Summary
- Career Highlights & Challenges
- · AprilBio’s Business Structure
- · AprilBio’s Governance Structure
- · Turned to Operating Profit Two Years After Listing
- · U.S. Partner Evommune Files for Nasdaq IPO
- · APB-R3’s Next Indication Set as Ulcerative Colitis
- · Accelerating Global Tech Transfers with Next-Generation Cancer Platform
- · Exploring REMAP Licensing Opportunities at BIO USA
- · APB-R3 Demonstrates Efficacy in Fatty Liver Disease Study Published in International Journal
- · Partnering with Japan’s EME to Develop Multi-Target Therapy Platform ‘REMAP’
- · Preclinical Results of Long-Acting Thyroid-Stimulating Hormone Released
- · APB-R3 Enters Global Phase 2 Clinical Trial
- · J.P. Morgan Becomes Second-Largest Shareholder of AprilBio
- · Receives US$5 Million Milestone from Lundbeck
- · Introducing ADC SAFA Platform at World ADC San Diego
- · Unveiling Next-Generation Drug Development Platform
- · US$475 Million Technology Transfer to U.S. Biotech Evommune
- · Safety Confirmed in Australian Phase 1 Trial Targeting IL-18 for Still’s Disease
- · CD40L Inhibitor Patent Registered in the United States
- · Signs MOU with ImmuneOncia for Joint Development of Immuno-Oncology Drugs
- · Yuhan Partners with AprilBio for SAFA-Based Long-Acting Drug Development
- · Listed on KOSDAQ in July 2022
- · US$432 Million Technology Transfer to Lundbeck
- · Signs MOU with Yuhan for Joint Drug Development
- · AprilBio’s Journey
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Family & Personal Connections
- Additional Information
- Notable Quotations
- Infographic & Photos